The week that was… your weekly market wrap (17-21 August)

Published 20-AUG-2018 11:19 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Corporate earnings season continued in Australia last week, with some companies disappointing the market, however, results were balanced, with a number of companies piquing investor interest writes Dale Gillham.

The good news for investors holding retail stocks, such as JB Hi-Fi (JBH) and Harvey Norman Holdings (HVN) is there’s no need to panic. Of note, following the release of JBH’s full year results on Monday, the stock had a fantastic week on the market. JBH’s share price rose by around 10 per cent to approximately $26. Following JBH’s all-time high of $31.21 in September 2016, this stock has been in decline, however, provided price continues to trade above $24.50 it is likely to trade up to challenge the prior high of $29.47.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

While the outlook appears to have improved for the retailer, the landscape in the retail space has changed. Competition for retailers with physical stores, from online competitors, such as Amazon and Ali baba has intensified. This means higher volatility in share prices.

Looking briefly at other sectors this week, the Healthcare (XHJ) sector is up by around 5 per cent, largely due to a strong rise in CSL Limited’s (CSL) share price, Industrials (XNJ) are up 2 per cent, Information Technology (XTJ) rose approximately 4 per cent and Utilities (XUJ) lifted approximately 2 per cent. It was good to see the Telecommunications sector, which Telstra (TLS) dominates, finally demonstrating there is light at the end of the tunnel. TLS’s price rose by around 5 per cent this week, pushing the sector off its low. Although Telstra announced a fall in profit of 8.4 per cent to $3.6 billion, as competition for mobile customers intensifies, it was news of the plan to roll out 20 new 5G towers by December that the market liked, driving the price above $3.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

What do we expect in the market?

The Australian market continued higher last week, which demonstrates confidence in the current corporate reporting season. The All Ordinaries Index (XAO) traded above 6,420 points cautiously, as most banks, excluding the Commonwealth Bank (CBA), moved higher.

Selling continued for Australian resources. The Energy (XEJ) sector fell by around 3 per cent and Materials (XMJ) was down by 1 per cent. Most commodity related stocks fell, including RIO Tinto (RIO), which recorded a decline of approximately 18 per cent from its May 2018 high of $87.09.

Dale Gillham is Chief Analyst of financial services company Wealth Within.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X